<a href="https://www.fiercebiotech.com/biotech/bristol-myers-800m-bispecific-adc-aces-breast-cancer-study-putting-trop2-drugs-notice" hreflang="en">ASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice</a>
Bristol Myers Squibb's bispecific antibody-drug conjugate, izalontamab brengitecan (iza-bren), demonstrated significant efficacy in a phase 3 trial for triple-negative breast cancer, reducing the risk of death by 40% compared to chemotherapy. The promising results position iza-bren as a strong competitor against established TROP2-directed therapies in the market.
Bristol Myers Squibb's bispecific ADC, izalontamab brengitecan (iza-bren), has shown promising phase 3 results in China for triple-negative breast cancer (TNBC), reducing the risk of death by 40% compared to chemotherapy. This positions iza-bren as a strong competitor against established TROP2-targeting ADCs like AstraZeneca's Datroway and Gilead's Trodelvy. For investors and stakeholders in healthtech and biotech, this development signals potential shifts in the TNBC treatment landscape, highlighting iza-bren's competitive edge and potential for broader application across multiple tumor types.